W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2…
Miasta: Gdańsk, Koszalin, Kraków, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
Miasta: Bielsko-Biala, Gdańsk, Gliwice, Katowice i 9 innych miastWiek: od 18 latSponsor: Polska Grupa Badawcza Chloniakow
RekrutujeFaza III
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal…
Miasta: Gdańsk, Koszalin, Kraków, Lublin i 2 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza II/III
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor…
Miasta: Gdańsk, Katowice, Kraków, Olsztyn i 7 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Miasta: Gdańsk, Gliwice, Olsztyn, Opole i 4 inne miastaWiek: od 18 latSponsor: Summit Therapeutics Inc.
RekrutujeFaza III
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Miasta: Koszalin, Kraków, Olsztyn, Warszawa i 1 inne miastoWiek: od 18 latSponsor: AstraZeneca AB
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Miasta: Bydgoszcz, Lublin, Olsztyn, Opole i 2 inne miastaWiek: od 0 latSponsor: Syndax Pharmaceuticals Inc.
RekrutujeFaza III
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Miasta: Białystok, Bydgoszcz, Koszalin, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Miasta: Koszalin, Olsztyn, Poznań, Tomaszów Mazowiecki i 1 inne miastoWiek: od 18 latSponsor: Pfizer Inc.
RekrutujeFaza III
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small…
Miasta: Gdańsk, Kielce, Lublin, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: BeOne Medicines AG
RekrutujeFaza III
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Miasta: Białystok, Bydgoszcz, Kielce, Koszalin i 7 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Miasta: Bydgoszcz, Gdańsk, Koszalin, Kraków i 3 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Miasta: Brzozów, Gliwice, Lubin, Lublin i 4 inne miastaWiek: od 18 latSponsor: Astellas Pharma Global Development Inc.
RekrutujeFaza II/III
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Miasta: Białystok, Katowice, Olsztyn, Poznań i 3 inne miastaWiek: od 18 latSponsor: Moleculin Biotech Inc.
RekrutujeFaza III
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Miasta: Białystok, Gdańsk, Koszalin, Olsztyn i 5 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received…
Miasta: Biała Podlaska, Białystok, Brzozów, Gdańsk i 5 innych miastWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza III
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse…
Miasta: Gliwice, Katowice, Lublin, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza II
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma…
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 4 inne miastaWiek: od 18 latSponsor: Medical University Of Gdansk
RekrutujeFaza III
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or…
Miasta: Biała Podlaska, Białystok, Brzozów, Gdańsk i 5 innych miastWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza III
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Miasta: Gdańsk, Legnica, Olsztyn, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Ascentage Pharma Group Inc.
RekrutujeFaza I/II
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Miasta: Gdańsk, Lublin, Olsztyn, Opole i 1 inne miastoWiek: od 18 latSponsor: BeOne Medicines AG
RekrutujeFaza II
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Miasta: Biała Podlaska, Bydgoszcz, Gdańsk, Gdynia i 8 innych miastWiek: od 18 latSponsor: Ryvu Therapeutics S.A.
RekrutujeFaza III
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Miasta: Katowice, Olsztyn, Poznań, Wrocław i 1 inne miastoWiek: od 18 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza III
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 12 innych miastWiek: od 18 latSponsor: Kartos Therapeutics Inc.
RekrutujeFaza III
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
Miasta: Białystok, Brzozów, Bydgoszcz, Chorzów i 12 innych miastWiek: od 18 latSponsor: Medical University Of Lodz
RekrutujeFaza III
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Miasta: Bielsko-Biala, Gliwice, Katowice, Koszalin i 5 innych miastWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited i jeszcze 1
RekrutujeFaza III
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small…
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Miasta: Białystok, Olsztyn, Poznań, WarszawaWiek: od 18 latSponsor: Shanghai Junshi Biosciences Co. Ltd.
RekrutujeFaza II
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Miasta: Gdańsk, Olsztyn, Opole, Skórzewo i 2 inne miastaWiek: 18-64 latSponsor: Pharmacosmos A/S
RekrutujeFaza III
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or…
Miasta: Bydgoszcz, Kraków, Legnica, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Grifols Therapeutics LLC